Budesonide for Liver Transplant Immune Suppression

NCT ID: NCT03304626

Last Updated: 2021-07-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-06-27
• Study Completion Date: 2019-12-31

Brief Summary

This is a pilot study that investigates the efficacy and safety of budesonide as an immune suppressing agent for liver transplant recipients in the early post-transplant period.

The primary end-point is rates of acute cellular rejection within first 24 weeks post-liver transplant. Secondary end points include rates of new onset diabetes after transplant and safety of budesonide.

The study is structured as a prospective clinical trial. After receiving 4 days of intravenous corticosteroids on liver transplant post-operative days 0 through 3, subjects will be started on standard immunosuppression plus enteric coated budesonide (study drug) in place of standard immune suppression plus prednisone (standard of care). Study drug will be tapered over 12 weeks in accordance with the existing standard of care immune suppression protocol. Subjects will be followed in outpatient transplant clinic for 24 weeks. The purpose of the study is to conduct a pilot study to generate rates and effect size that can be used in a subsequent equivalent trial. A total of 20 subjects will be enrolled to receive the standard immunosuppression plus budesonide and their outcomes will be compared to 20 controls receiving standard immunosuppression plus prednisone (standard of care). The use of controls is to generate rate and variability that can be compared with the rate obtained from patients that receive study drug by examining the 95% confidence band.

Detailed Description

Enrollment of Subjects: All consecutive patients undergoing liver transplant (LT) at the University Of Cincinnati Transplant Center will be screened for enrollment upon admission for transplant surgery. Subjects will be approached after permission from attending on record by one of the members of research team. Study rationale, procedures, different interventions, potential benefits and risks as well as alternatives to study participation will be explained to the subjects in their native language in non-medical terms, as much possible. For non-English speakers, certified interpreter services will be used. Subjects meeting all of the inclusion and none of the exclusion criteria will be educated about the study and written informed consent will be obtained either 12 hours prior to undergoing LT or within 72 hours of completion of a successful transplant surgery. This time frame is proposed so that subjects have sufficient time to go over the study and are not pressured to sign the consent within a short time frame prior to LT surgery. In addition, all patients being placed on liver transplant list at our center will be provided with a copy of the consent form in the LT clinic at the time of listing for review only so that this study proposal is not completely novel to them at the time of LT surgery. A pregnancy test will be performed on all the females of childbearing potential.

Enrollment of Controls:

Each study subject will be matched with a control subject. Patients undergoing LT at University of Cincinnati that are not part of the study will serve as controls. Confounding and effect modifiers will be accounted for by matching the controls on multiple variables which may affect the primary outcome of ACR. These variables include: age less than 55 years, serum creatinine greater than 1.5 ng/mL, the use of antibody therapy at the time of transplant and a history of autoimmune hepatitis. To minimize the selection bias, the matched control will be selected in a manner that he/she would have undergone liver transplantation within a 24 week period (8 weeks prior or 16 weeks after) of the liver transplantation of the matched study subject. This means that data from controls will also be collected prospectively. Since outcomes are being measured at week 24 of liver transplantation, this will ensure that the investigators have no influence on selecting the controls with a known outcome. Controls will be identified through LT clinic. They will not undergo any study specific procedures, interventions, testing or evaluations. A written and informed consent will be obtained from all controls prior to their enrollment in the study. University of Cincinnati transplant program has performed 90-100 LTs each year over last 2 calendar years. Application of inclusion and exclusion criteria of our study to this database estimates that 65% of all LTs will be potential candidates for participation either as study subject or control. Based on this estimate the investigators are confident that this enrollment goal of 20 subjects and 20 controls can be achieved in 9-12 month period.

Study Drug:

After LT surgery, subjects will be started on SIS including intravenous corticosteroids, calcineurin inhibitor (CNI), mycophenolate mofetil (MMF) +/- thymoglobulin as per University of Cincinnati LT immune suppression protocol (UC-ISP).

On post-operative day 4, intravenous corticosteroids will be discontinued and replaced by the study drug; budesonide. Based on pharmacokinetic and bioavailability studies, 3 mg of budesonide is equivalent to 10 mg of prednisone. Starting dose of budesonide will be 9 mg by mouth daily which will be equivalent to 30-40 mg of prednisone used as standard of care. Study drug will be tapered over the next 3 months as detailed in Table 1 and in line with UC-ISP. At 3 months post LT, study drug will be discontinued. Subjects with autoimmune hepatitis as an etiology for LT will be initiated on prednisone 5 mg daily in addition to SIS as per UC-ISP.

Table 1: Study Drug Taper Time post Liver Transplantation Immunosuppressive therapy Days 0-3 Standard immune suppression (SIS) + Intravenous corticosteroids Days 4-30 SIS + Budesonide 9 mg Days 31-45 SIS + Budesonide 6 mg Days 46-90 SIS + Budesonide 3 mg Days 90 onwards SIS

Study Assessments (Visits 3-7):

Subjects will undergo study visits in the LT clinic or inpatient transplant unit at post-LT weeks 2,4,6,8 and 12 (Figure 1). At each visit, data regarding history and physical, vital signs, concomitant medications, use of hypoglycemic agents or insulin, adverse event assessment, laboratory blood work including blood counts, chemistries, blood glucose, liver function test, and tacrolimus trough level will be recorded. Blood samples for early morning cortisol level (between 6 AM and 9 AM) will be collected at week 4 and week 8 visits only. These samples will be centrifuged at 3600 rpm for 15 minutes, appropriately labelled and stored in - 80 C freezer at Schubert Research Clinic. All the samples from the study will be analyzed for serum cortisol in 1-2 batches to ensure uniform and standardized testing conditions and reagents. No other testing will be performed on these samples. Hemoglobin A1c will be checked at week 12 (visit 7). Additionally, at each visit, the study team will perform a pill count for the study drug. Study drugs will be dispensed every 4 weeks at study visits 2, 4 and 6. Decisions regarding obtaining a liver biopsy for evaluation of abnormal liver tests will be at the discretion of treating physician. Biopsy proven ACR will be treated according to UC-Rejection protocol.

Study drug will be discontinued at week 12 (visit 7) and subjects will continue routine post-LT follow up as per the current standard of care.

A low dose ACTH stimulation test will be performed at Schubert Research Clinic at week 12 visit. This test comprises of intravenous injection of cosyntropin at a dose of 1 micrograms per 1.73 m2 of body surface area and checking the serum cortisol levels at baseline and 30 minutes after cosyntropin injection. This test is used to assess adrenal insufficiency with a high sensitivity.

Conditions

Acute Cellular Graft Rejection; New Onset Diabetes After Transplant

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Study Group

Budesonide EC 3 mg capsule. The dose will be as follows

Time post Liver Transplantation Immunosuppressive therapy Days 0-3 Standard immune suppression (SIS) + Intravenous corticosteroids Days 4-30 SIS + Budesonide 9 mg Days 31-45 SIS + Budesonide 6 mg Days 46-90 SIS + Budesonide 3 mg Days 90 onwards SIS1

Group Type: EXPERIMENTAL

Budesonide 3Mg Capsule

Intervention Type: DRUG

Budesonide capsule in place of prednisone (standard of care)

Control Group

Standard of Care

Time post Liver Transplantation Immunosuppressive therapy Days 0-3 Standard immune suppression (SIS) + Intravenous corticosteroids Days 4-30 SIS + Prednisone 15-60 mg Days 31-45 SIS + Prednisone 10 mg Days 46-90 SIS + Prednisone 2.5 to 7.5 mg Days 90 onwards SIS

Group Type: ACTIVE_COMPARATOR

Standard of Care Prednisone

Intervention Type: DRUG

Prednisone taper (Standard of Care)

Interventions

Budesonide 3Mg Capsule

Budesonide capsule in place of prednisone (standard of care)

Intervention Type: DRUG

Standard of Care Prednisone

Prednisone taper (Standard of Care)

Intervention Type: DRUG

Other Intervention Names

Entocort EC; Prednisone

Eligibility Criteria

Inclusion Criteria

• Female or male subjects aged 21-75 years old
• Received a primary liver transplant within 4 days of enrollment

Exclusion Criteria

• Received previous organ transplants
• Undergoing multiple organ transplants
• Recipients with advanced fibrosis in graft
• Treatment plan for subject includes receiving immunosuppressant therapy other than standard immune suppression (SIS) as per University of Cincinnati LT immune suppression protocol (UC-ISP).
• Inability to take enteral (orally or by tube feed) medications by day 4 post-transplant
• Subjects with diabetes mellitus prior to transplant (diabetes mellitus defined as use of hypoglycemic agents or HbA1c > 6.4 prior to transplant)
• Subjects who have any severe medical condition requiring acute or chronic treatment that in the investigator's opinion would interfere with study participation.
• Subjects who have been exposed to an investigational therapy within 30 days prior to enrollment or 5 half-lives on the investigational product, whichever is greater.
• Subjects in which concomitant use of medications which are inhibitors of CYP3A4 (such as ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, erythromycin) cannot be avoided during the study period.
• Pregnant females
• Diminished mental capacity to consent for the study as determined by attending on the record.

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

American College of Gastroenterology

OTHER

Sponsor Role: collaborator

University of Cincinnati

OTHER

Sponsor Role: lead

Responsible Party

Khurram Bari

Assistant Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

University of Cincinnati Medical Center

Cincinnati, Ohio, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

2016-1488

Identifier Type: -

Identifier Source: org_study_id